=Glenmark Pharmaceuticals the drug firm on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet (Pack of 34 Medicines at 3500 RS)
FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it added.
It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said.
Moreover, it is an oral product and that is a huge benefit especially when the hospital infrastructure is under strain, he added.
Manufacturing and marketing consent has been granted as part of an accelerated approval process, considering the emergency situation of Covid-19 outbreak in India, the drugmaker said.
Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases, it said.
Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.
